NGHIÊN CỨU TÍNH PHÙ HỢP TRONG SỬ DỤNG THUỐC ĐIỀU TRỊ RỐI LOẠN LIPID MÁU TRÊN BỆNH NHÂN NỘI TRÚ TẠI BỆNH VIỆN ĐẠI HỌC Y DƯỢC CẦN THƠ NĂM 2022-2023

Abstract

Background: Dyslipidemia is prevalent in the community through epidemiology and treatment of RLLM also carries a great preventive significance for vascular risk. Objectives: Determining the characteristics of drug use and assessing the suitability of the use of drugs to treat blood lipid disorders in inpatient patients at Can Tho University Hospital of Medicine and Pharmacy in 2022-2023. Materials and methods: To conducte descriptive cross-sectional research on 189 medical records at the internal department of Can Tho University of Medicine and Pharmacy Hospital from June 2022 to May 2023. The data is collected from the patient's medical record. Results: The statin group was the most used at 96.8%; medium strength statins dominated with 93.5%, of which, atorvastatin 10mg (57.1%), atorvastatin 20mg (32.8%), atorvastatin 40mg (3.7%), rosuvastatin 20mg (2.6%), rosuvastatin 10mg (1.1%). Appropriate drug decision rate is 96.3%; appropriate drug selection is 96.8%; appropriate drug dose is 90.5%; serious drug interactions in the application is 4.2%. The overall appropriate rate of drug use for dyslipidemia is 80.4%. Conclusion: The rate of inappropriate drug use is related to the doctor's prescription, so the doctor needs to individualize each patient to take appropriate drug use measures as well as prevent and control cardiovascular events.